Skip to main content
Swing Capital

Venus Remedies Ltd

NSE: VENUSREM BSE: 526953Pharma

Incorporated in 1989, Venus Remedies Ltd is a research based pharmaceutical company and an injectable manufacturer[1]

₹959
52W: ₹332 — ₹1119
PE 18.2 · Book ₹467 · +105% vs book
Market Cap₹1,282 Cr
Stock P/E18.2Price to Earnings
ROCE11.9%Return on Capital
ROE8.1%Return on Equity
Div. Yield0%Face Value ₹10

Strengths

  • +Company has reduced debt.
  • +Company is almost debt free.

Weaknesses

  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has a low return on equity of 6.87% over last 3 years.

Shareholding Pattern

Promoters41.76%
FIIs2.8%
DIIs1.2%
Public54.24%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%
FIIs1.06%1.18%▲0.11.11%▼0.11.34%▲0.22.25%▲0.91.86%▼0.42.25%▲0.42.8%▲0.5
DIIs0%0%0%0%0.11%▲0.10.75%▲0.61.03%▲0.31.2%▲0.2
Public57.17%57.06%▼0.157.13%▲0.156.9%▼0.255.89%▼1.055.62%▼0.354.95%▼0.754.24%▼0.7

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales170131175106170172194137193180
Expenses15711815492157150171119163143
Operating Profit13132114132323183037
OPM %8%10%12%13%8%13%12%13%15%20%
Net Profit5813492415121925
EPS ₹4.086.139.363.336.9318.0111.068.7514.3918.64

AI Insights

Revenue Trend

TTM revenue at ₹704Cr, up 11.6% YoY. OPM at 15%.

Debt Position

Borrowings at ₹1Cr. Debt-to-equity ratio: 0.00x. Healthy balance sheet.

Capex Cycle

CWIP at ₹34Cr (15% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 1.2% (+1.20pp change). FIIs: 2.8% (+1.82pp change). Promoters hold 41.76%.

Margin & Efficiency

ROCE declining from 13% (Mar 2014) to 12% (Mar 2025). Working capital days: 97.

Valuation

PE 18.2x with 11.9% ROCE. Price is 105% above book value of ₹467. Dividend yield: 0%.

Recent Announcements